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Background. The aims of this study were to analyze the clinical characteristics of SPM in patients with well-differentiated thyroid
cancer and to determine the long-term prognosis in patients with double malignancies.Materials and Methods.We retrospectively
analyzed 2,864 patients with well-differentiated thyroid cancer and a mean age of 44.0 ± 14.4 years. Of these, 200 (7.0%) were
diagnosed with SPM, 115 of which were diagnosed with metachronous SPM. Results. Of 2,864 patients, 163 (5.7%) patients died
of thyroid cancer and 301 (10.5%) died of any cause by the end of the follow-up period. Multivariate analysis identified age,
SPM, external radiotherapy, TNM stage, and postoperative serum Tg level to be factors independently associated with decreased
survival. Of 200 patients with SPM, 74 (37.0%) died. In comparison to the anachronous and synchronous groups, themetachronous
SPM group had a higher mean age; more advanced tumor, node, and metastasis stage; lower remission rate; higher postoperative
radioactive iodide (131I) accumulated dose; a higher proportion of patients who underwent external radiotherapy; and higher
thyroid cancer and total mortality rates. Conclusions. Patients with well-differentiated thyroid carcinoma and metachronous SPM
had worse prognoses compared to patients without SPM.
1. Introduction
Thyroid cancer is the most common endocrine cancer and
one of the malignancies with the most rapidly increasing
frequency over the last few decades [1–3]. Majority of thyroid
cancers are well-differentiated and include the papillary and
follicular types [4]. Most patients with well-differentiated
thyroid carcinoma have excellent prognoses after appropri-
ate therapy. To avoid the over- or underadministration of
postthyroidectomy therapeutic modalities in patients with
thyroid cancer, the stratification of the risk of recurrence and
thyroid cancermortality is urgently needed [5, 6]. An elevated
risk of second primary malignancy (SPM), possibly related
to radioactive iodide (131I), was recently reported in patients
with thyroid cancer [7, 8]. During the follow-up period, the
diagnosis and identification of SPM risk factors in patients
with well-differentiated thyroid cancer are important. The
development of SPMmay influence the prognosis in patients
with thyroid cancer. The purpose of this study was to analyze
the clinical characteristics of SPM in patients with well-
differentiated thyroid cancer of follicular cell origin and to
determine the long-term prognosis in patients with double
malignancies.
2. Materials and Methods
Between 1984 and 2013, 2,864 patients with well-differ-
entiated thyroid carcinoma including 2,568 with papillary,
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254 with follicular, and 42 with Hürthle cell carcinoma
underwent thyroidectomy and long-term follow-up at Chang
GungMemorial Hospital in Linkou, Taiwan.The thyroid car-
cinomas were pathologically classified according to the 2004
World Health Organization criteria [9]. After the operation,
all patients were staged using the American Joint Commit-
tee on Cancer-Tumor-Node-Metastasis (TNM) criteria (7th
edition) [10]. In our center, most patients who had well-
differentiated thyroid carcinoma with a tumor size > 1 cm
underwent total thyroidectomy. Central or lateral dissection
was performed for clinically enlarged lymph nodes or an
extrathyroidal extension.
Thyroid remnant ablation was performed 4–6 weeks
after thyroidectomy in 1,168 of 2,864 patients with well-
differentiated thyroid carcinoma. The 131I ablation dose for
most high-risk patients was 3.7 GBq (100mCi). A whole-
body scan (WBS) was performed 1 week after 131I admin-
istration. Levothyroxine (LT4) treatment was then initiated
to reduce the thyroid-stimulating hormone (TSH) level
without inducing clinical thyrotoxicosis. Therapeutic doses
were in the range of 3.7–7.4GBq (100–200mCi) for cases
of locoregional recurrence or distant metastasis. According
to the radiation regulations in Taiwan, patients receiving <
1.1 GBq are classified as outpatients.
In patients who did not have a detectable 131I uptake
beyond the thyroid bed during postablation WBS, thyroid
hormone treatment was withdrawn after 6–12 months, and
thyroglobulin (Tg), TSH, and anti-Tg antibody measure-
ments were performed. SPM was diagnosed in patients with
thyroid cancer based on the malignancy diagnosis code,
defined by codes from 140 to 208.91 in ICD-9 clinical modi-
fication format. Patients with malignant neoplasms required
diagnostic validation by at least two specialists based on
medical record examination, laboratory and imaging results,
and histological or cytological analyses. Patients diagnosed
with malignant neoplasms were categorized into different
groups according to the anatomic organ system. Depending
on the timing of diagnosis, SPM was categorized into two
groups: (1) anachronous (diagnosed 6 months before thyroid
cancer diagnosis) or synchronous and (2) metachronous
(diagnosed 6 months after thyroid cancer diagnosis). All
subjects were Chinese residents of Taiwan. The study was
approved by the Institutional Review Board of Chang Gung
Memorial Hospital (CGMH).
The thyroid cancer database of CGMH in Linkou was
established in 1995 and updated every 1-2 years. Data on
patient age, sex, primary tumor size, ultrasonography results,
fine needle aspiration cytology results, and thyroid function
before and after surgery; surgical methods, histopatholog-
ical findings, and TNM staging; 4–6 weeks’ postoperative
serum Tg levels, anti-Tg antibody levels, diagnostic results,
therapeutic 131I scans, 131I accumulated dose, and chest
radiography findings; and clinical status for the analysis of
distant metastases via noninvasive radiological and nuclear
medical studies, external radiotherapy site and dose, treat-
ment outcomes, SPM diagnosis date and histopathology,
causes of death, and survival status were recorded. At the
end of 2013, patients were categorized into thyroid cancer
remission and nonremission groups. Nonremission was defi-
ned as cytopathologically proven residual or recurrent status
or positive imaging studies with detectable Tg after the
withdrawal of thyroxin treatment.
Categorical data were compared using the Pearson chi-
squared or Fisher’s exact test for small size datasets. Continu-
ous data were compared between the groups using unpaired
𝑡-test. Total and thyroid cancer-related mortalities were cal-
culated, and the follow-up period was extended from the date
of diagnosis to the date of last cancer-relatedmortality among
patients who were followed up. Survival rates were calculated
using the Kaplan-Meier method and compared using the
log-rank test [11]. A multivariate Cox proportional hazards
regression model was used to estimate the mortality risk. All
statistical analyses were performed using SPSS version 17.0
statistical software (SPSS Inc., Chicago, IL, USA). 𝑝 values <
0.05 were considered statistically significant in all tests.
3. Results
The 2,864 patients with well-differentiated thyroid carci-
noma, 2,256 (78.0%) of which were women, had a mean
age of 44.0 ± 14.4 years. The mean tumor size was 2.4 ±
1.7 cm, and 84.7% (2,425/2,864) of the patients underwent
total thyroidectomy with or without lymph node dissection.
A total of 1,950 (68.1%) cases were categorized as TNM stage I
(Table 1). Over a mean follow-up period of 9.5±6.7 years, 163
(5.7%) patients died of thyroid cancer. However, 301 (10.5%)
patients had died of any cause by the end of the follow-up
period.
Table 1 shows the clinical features of patients with
well-differentiated thyroid cancer and those with and
without SPM. The SPM group had a greater proportion of
men, higher mean age, more advanced TNM stage, higher
nonremission rate, higher 131I accumulated dose, higher
proportion of patients who underwent external radiotherapy,
and higher total and thyroid cancer mortality rates. Over a
mean follow-up period of 9.2 ± 6.6 years, 74 (37.0%) patients
died (Table 1). Table 2 illustrates the multivariate analysis by
Cox proportional hazards regression model for survival and
overall mortality of the 2,864 patients withwell-differentiated
thyroid cancer. Age, SPM, external radiotherapy, TNM stage,
and postoperative serum Tg level were significantly higher
in the mortality group.
Figure 1 illustrates the age and sex distribution of SPM
cases by number and percentage. Two hundred patients were
diagnosed with SPM. The incidences of thyroid cancer and
SPM peaked at patient ages of 30–40 years and 50–60 years,
respectively. Among the 200 patients with SPM, 115 (57.5%)
were diagnosed with metachronous SPM. Forty percent of
metachronous SPM cases were diagnosed in the 5 years
after thyroid cancer treatment (Figure 2). The histological
pattern and organ system of SPM are shown in Supplemen-
tal Table A, in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/9570171. Of the three leading
histological patterns of SPM, the oral cavity and pharynxwere
more commonly affected in the anachronous or synchronous
group. In contrast, the digestive system was more commonly
affected in the metachronous group. The incidence of breast
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Table 1: Clinical features of 2,864 cases of well-differentiated∗ thyroid cancer with or without second primary malignancies (SPMs) between
1984 and 2013.
Clinical characteristic Total With SPM Without SPM 𝑝
Patient number 2,864 200 (7.0%) 2,664 (93.0%)
Gender (female) 2,256 (78.8%) 139 (69.5%) 2,117 (79.5%) 0.0009
Age at diagnosis (year) 44.0 ± 14.4 51.6 ± 13.2 43.5 ± 14.4 0.0001
Mean tumor size (cm) 2.4 ± 1.7 2.4 ± 1.5 2.4 ± 1.7 0.6793
Thyroid operative method 0.0035
Total thyroidectomy 2425 (84.7%) 155 (77.5%) 2270 (85.2%)
Less than total thyroidectomy 439 (15.3%) 45 (22.5%) 394 (14.8%)
TNM stage 0.0001
Stage I 1950 (68.1%) 101 (50.5%) 1849 (69.4%)
Stage II 287 (10.0%) 27 (13.5%) 260 (9.8%)
Stage III 229 (8.0%) 25 (12.5%) 204 (7.6%)
Stage IV 398 (13.9%) 47 (23.5%) 351 (13.2%)
Nonremission 466 (16.3%) 48 (24.0%) 418 (15.7%) 0.0021
Follow-up period (year) 9.5 ± 6.7 9.2 ± 6.6 9.5 ± 6.7 0.5575
Postoperative 131I accumulative dose (mCi) 130.6 ± 193.6 166.3 ± 258.2 127.9 ± 187.6 0.0068
Radiation therapy 143 (5.0%) 24 (12.0%) 119 (4.5%) 0.0001
Multifocality 662 (23.1%) 50 (25.0%) 612 (23.0%) 0.5119
Mortality due to thyroid cancer 163 (5.7%) 18 (9.0%) 145 (5.4%) 0.0362
Overall mortality 301 (10.5%) 74 (37.0%) 227 (8.5%) 0.0001
∗Well-differentiated: including papillary, follicular, and Hürthle’s cell thyroid cancer.
Table 2: Multivariate analysis by Cox proportional hazards regression model for survival and total mortality in 2,864 patients with well-
differentiated thyroid cancer.
𝛽 coefficient Hazard ratio 95% confidence interval 𝑝 value
Lower bound Upper bound
Age (year) 0.071 1.074 1.0598 1.0880 0.0000
Gender (F/M) 0.275 1.317 0.9743 1.7790 0.0733
SPM∗ (without/with SPM) 0.860 2.363 1.6987 3.2861 0.0000
Postop 131I accumulative dose (mCi) 0.000 0.999 0.9995 1.0004 0.7388
Radio therapy (no/yes) 1.289 3.628 2.5705 5.1209 0.0000
TNM stage (SI/SII/SIII/SIV) 0.260 1.305 1.1317 1.5056 0.0003
Postop 1-month Tg (ng/mL) 0.000 1.000 1.0000 1.0001 0.0000
Tumor size (cm) 0.0462 1.047 0.9896 1.1082 0.1099
Thyroid operative method (less than total/total thyroidectomy) −0.2960 0.744 0.5023 1.1014 0.1395
∗SPM: second primary malignancy.
cancer was similar between the two groups. Supplemen-
tal Figure illustrated age and case number of top three
metachronous SPMs. To discern the influence of thyroid
cancer and treatment on the metachronous SPM group,
we compared the clinical characteristics of patients with
metachronous SPM to those with papillary thyroid cancer
(Supplemental Table B). The metachronous SPM group had
a higher mean age, less aggressive surgical treatment, more
advanced TNM stage, higher nonremission rate, highermean
postoperative 131I accumulated dose, higher proportion of
patients who underwent external radiotherapy, and higher
thyroid cancer and total mortality rates. In addition, overall
mortality was higher in patients with metachronous SPM
compared to those with anachronous or synchronous SPM;
however, the differencewas not statistically significant (42.6%
versus 29.4%, 𝑝 = 0.056).
Figure 3(a) illustrates Kaplan-Meier survival curves of
thyroid cancer and overall mortality of the SPM and non-
SPM patients. For all patients, those with SPM, and those
without SPM, the 5-year survival rates were 93.5%, 80.4%,
and 95.0%, respectively; the 10-year survival rates were 89.3%,
69.6%, and 90.9%, respectively; and the overall survival
rates were 80.9%, 41.7%, and 84.8%, respectively. There was
a statistically significant difference between the SPM and
non-SPM groups (𝑝 = 0.0001). In contrast, there was
no statistical difference of overall survival rates between
metachronous group and anachronous with synchronous
group (Figure 3(b)). Breast cancer was the most common
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Table 3: Clinical features of 200 cases of well-differentiated thyroid cancer∗ with second primarymalignancy (SPM) as breast cancer or other
cancers.
Clinical characteristic All patients Breast cancer Other cancers p value
Patient number 200 45 (22.5%) 155 (77.5%)
Gender (female) 139 (69.5%) 45 (100.0%) 94 (60.6%) 0.0001
Age at diagnosis (year) 51.6 ± 13.2 47.1 ± 10.2 52.9 ± 13.7 0.0099
Mean tumor size (cm) 2.4 ± 1.5 2.2 ± 1.2 2.4 ± 1.6 0.5271
Thyroid operative method 0.4470
Total thyroidectomy 155 (77.5%) 33 (73.3%) 122 (78.7%)
Less than total thyroidectomy 45 (22.5%) 12 (26.7%) 33 (21.3%)
TNM stage 0.0518
Stage I 101 (50.5%) 26 (57.8%) 75 (48.4%)
Stage II 27 (13.5%) 9 (20.0%) 18 (11.6%)
Stage III 25 (12.5%) 6 (13.3%) 19 (12.3%)
Stage IV 47 (23.5%) 4 (8.9%) 43 (27.7%)
Nonremission 48 (24.0%) 5 (11.1%) 43 (27.7%) 0.0215
Follow-up period (year) 9.2 ± 6.6 9.6 ± 6.0 9.1 ± 6.7 0.6467
Postoperative 131I accumulative dose (mCi) 166.3 ± 258.2 95.1 ± 102.1 187.0 ± 284.8 0.0357
131I dose ≥ 30mCi 167 (83.5%) 40 (88.9%) 127 (81.9%) 0.2686
Radiation therapy 24 (12.0%) 1 (2.2%) 23 (14.8%) 0.0219
Time to metachronous SPM diagnosis (year) [range] 7.7 ± 5.7 [0.5–22.2] 7.5 ± 5.2 [0.6–21.2] 7.8 ± 5.8 [0.5–22.2] 0.8190
Multifocality 50 (25.0%) 10 (22.2%) 40 (25.8%) 0.6250
Mortality due to thyroid cancer 18 (9.0%) 1 (2.2%) 17 (11.0%) 0.0711
Overall mortality 74 (37.0%) 6 (13.3%) 68 (43.9%) 0.0002
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Figure 1: Number and percentage of second primary malignancies
by age and sex.
SPM in patients with thyroid cancer, followed by the digestive
system cancers. Among the 45 patients with breast cancer, 18
were diagnosed before or during thyroid cancer treatment.
All the patients with thyroid cancer and breast cancer were
female. Compared to the other SPM group, the breast cancer
group had a lower mean age, lower nonremission rate, lower
131I accumulated dose, and lower proportion of patients
who underwent external radiotherapy (Table 3). In addition,
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Figure 2: Case number of metachronous SPM after thyroidectomy.
the thyroid cancer and total mortality rates were lower in
breast cancer patients compared to those with other SPMs.
4. Discussion
SPM is reported to be involved in approximately 18% of
cases of malignant tumor in the United States [12]. Most
patients with well-differentiated thyroid cancer have good
prognoses; however, SPM in patients with thyroid cancermay
be a major cause of mortality and serious morbidity among
thyroid cancer survivors. In this study, 4.01% (115/2,864) of
patients with well-differentiated thyroid carcinoma also had
metachronous SPM. This ratio is higher compared to that
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Figure 3: (a) Kaplan-Meier survival curves of thyroid cancer and overall mortality of the SPM and non-SPM patients. (b) Overall survival
rates between metachronous group and anachronous with synchronous group.
recently reported by a study conducted on a large patient
cohort with thyroid cancer in Korea (1.6%; 2,895/178,844
patients with thyroid cancer) [7]. In addition, the SPM
cancer type was different in these studies. In our study, the
incidences of leukemia (4.3%) and lymphoma (3.5%) were
low in patients with metachronous SPM. A higher incidence
of SPM (13.04%) in patients with thyroid cancer was reported
by Zafon et al. [13]. The results of their study are similar
to ours in that male patients and older patients were more
likely to have SPM.The reason for this ethnic and geographic
diversity in SPM in patients with thyroid cancer requires
further investigation.
Our data illustrated that SPM in patients with well-
differentiated thyroid carcinoma presented with a more
advanced TNM stage and higher thyroid cancer-specific and
overall mortality compared to patients without SPM. In
a recent study, breast cancer was the most common syn-
chronous or antecedent nonthyroidal malignancy in women
with well-differentiated thyroid carcinoma [14, 15]. SPM of
digestive system, oral cavity, or pharynx origin was more
common in this area than in Western countries [16].
As indicated in our study, incidental thyroid cancer (ITC)
may be diagnosed, followed by anachronous or synchronous
SPM of the oral cavity and pharynx. ITC may present during
neck surgery for nonthyroid disease [17]. In a recent study, of
the 690 patients with head and neck cancer, 234 (33.9%) had
incidental thyroid lesions on ultrasonography, 9.4% of which
were definitively diagnosed as thyroid cancer. Occasional
papillary thyroid carcinoma occurred in the lymph nodes of
patients with head and neck cancer who underwent radical
neck dissection. Characteristic findings of thyroid origin
demonstrated thyroid follicular structure and positive Tg
staining on immunohistochemical analysis [18].
Controversy concerning the effect of 131I treatment on the
occurrence of SPM in patients with thyroid cancer persists
[8, 19, 20]. Previous studies had different study designs,
varying follow-up periods, and different 131I dosages, which
made an accurate comparison difficult. A meta-analysis of
two multicenter studies by Blumhardt et al. concluded that
the risk of SPM in thyroid cancer patients treated with 131I
is slightly higher compared to the risk in thyroid cancer
survivors not treated with 131I [21]. Our study showed that
patients withmetachronous SPMand thyroid cancer received
higher accumulated doses compared to patients without
SPM. In our study, after a mean follow-up period of 11.7±6.6
for patients with metachronous SPM and thyroid cancer, the
total mortality rate was 42.6%. We therefore agree with the
recommendation from Tuttle’s group that 131I therapy needs
to be “rationed” in low-risk patients with well-differentiated
thyroid cancer [20].
In our study, all the patients with breast cancer in
the SPM group were female. Female sex is known as the
dominant characteristic of patients with well-differentiated
thyroid cancer. There were 2,256 (78.8%) female patients in
our study group. Of the 139 women with SPM, 45 (32.4%)
had breast cancer; 18 of them were diagnosed with it before
or concomitantly with the thyroid cancer. A recent study
showed that radiotherapy for breast cancer is significantly
associated with an increased risk of a second nonbreast
cancer both overall and in organs adjacent to the previous
treatment fields [22]. Consistent with previous studies, in our
study, synchronous primary cancers of the thyroid and breast
were common findings [15]. A recent study showed that 131I
therapy for thyroid cancer did not increase the incidence or
recurrence rate of breast cancer [23]. Consistent with our
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data, the accumulated dose of 131I in patients with breast
cancer and SPM was significantly lower than that in other
patients with SPM. In comparison to a previous study, breast
cancer was the most common synchronous and antecedent
nonthyroidal malignancy in patients with thyroid cancer
[14]. In contrast, prostate cancer, melanoma, and renal cell
carcinoma are unusual SPMs in this area. SPMs of oral cavity,
pharynx, or digestive system origin were more common.
Breast, colon, and lung cancer are the three most prevalent
types of cancer among women in Taiwan [24]. In our study,
approximately 80% of patients were women. In addition, the
histological type of the SPM in our patients was similar to that
in the general population. This information might indicate
that no specific cancer was the result of thyroid cancer
treatment and the application of 131I and external radiation in
our study did not increase specific SPM histological pattern.
5. Conclusion
SPM is common in patients with well-differentiated thyroid
cancer. The overall mortality in patients with thyroid cancer
and SPM may increase to 4.4 times higher than that of
patients without SPM. Breast cancer and digestive system
malignancies are the most common SPMs. During long-
term follow-up, sites of high SPM incidence need to be more
closely examined.
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